Endothelin System in Hypertension and Chronic Kidney Disease
ET (endothelin) is a powerful vasoconstrictor 21-amino acid peptide present in many tissues, which exerts many physiological functions across the body and participates as a mediator in many pathological conditions. ETs exert their effects through ETA and ETB receptors, which can be blocked by selective receptor antagonists. ETs were shown to play important roles among others, in systemic hypertension, particularly when resistant or difficult to control, and in pulmonary hypertension, atherosclerosis, cardiac hypertrophy, subarachnoid hemorrhage, chronic kidney disease, diabetic cardiovascular disease, scleroderma, some cancers, etc. To date, ET antagonists are only approved for the treatment of primary pulmonary hypertension and recently for IgA nephropathy and used in the treatment of digital ulcers in scleroderma. However, they may soon be approved for the treatment of patients with resistant hypertension and different types of nephropathy. Here, the role of ETs is reviewed with a special emphasis on participation in and treatment of hypertension and chronic kidney disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
|---|---|
| Enthalten in: |
Hypertension (Dallas, Tex. : 1979) - 81(2024), 4 vom: 27. März, Seite 691-701 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schiffrin, Ernesto L [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 29.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1161/HYPERTENSIONAHA.123.21716 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365502634 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365502634 | ||
| 003 | DE-627 | ||
| 005 | 20240330000618.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/HYPERTENSIONAHA.123.21716 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1355.xml |
| 035 | |a (DE-627)NLM365502634 | ||
| 035 | |a (NLM)38059359 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schiffrin, Ernesto L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endothelin System in Hypertension and Chronic Kidney Disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ET (endothelin) is a powerful vasoconstrictor 21-amino acid peptide present in many tissues, which exerts many physiological functions across the body and participates as a mediator in many pathological conditions. ETs exert their effects through ETA and ETB receptors, which can be blocked by selective receptor antagonists. ETs were shown to play important roles among others, in systemic hypertension, particularly when resistant or difficult to control, and in pulmonary hypertension, atherosclerosis, cardiac hypertrophy, subarachnoid hemorrhage, chronic kidney disease, diabetic cardiovascular disease, scleroderma, some cancers, etc. To date, ET antagonists are only approved for the treatment of primary pulmonary hypertension and recently for IgA nephropathy and used in the treatment of digital ulcers in scleroderma. However, they may soon be approved for the treatment of patients with resistant hypertension and different types of nephropathy. Here, the role of ETs is reviewed with a special emphasis on participation in and treatment of hypertension and chronic kidney disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a diabetic nephropathies | |
| 650 | 4 | |a endothelin receptor antagonists | |
| 650 | 4 | |a glomerulosclerosis, focal segmental | |
| 650 | 4 | |a vascular remodeling | |
| 650 | 7 | |a Endothelin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Endothelins |2 NLM | |
| 650 | 7 | |a Endothelin-1 |2 NLM | |
| 650 | 7 | |a Receptors, Endothelin |2 NLM | |
| 650 | 7 | |a Receptor, Endothelin A |2 NLM | |
| 700 | 1 | |a Pollock, David M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hypertension (Dallas, Tex. : 1979) |d 1983 |g 81(2024), 4 vom: 27. März, Seite 691-701 |w (DE-627)NLM000456136 |x 1524-4563 |7 nnns |
| 773 | 1 | 8 | |g volume:81 |g year:2024 |g number:4 |g day:27 |g month:03 |g pages:691-701 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/HYPERTENSIONAHA.123.21716 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 81 |j 2024 |e 4 |b 27 |c 03 |h 691-701 | ||